Medical R&D news, white papers, reports, and events from PharmaLeaders. New content daily, on our website and delivered right to your inbox.
Now is the time to update Stark law, HHS, providers tell Congress HHS joined Advocate Aurora Health on Tuesday to urge Congress to tweak a long-time anti-kickback law they say is scaring providers from entering into value-based care models. The Stark law prohibits doctors from referring Medicare patients to hospitals, labs and colleagues with whom they have financial relationships unless they fall under certain exceptions. Physicians and hospitals ... Read More
$313M Medicare auditor contract goes to Noridian Noridian Healthcare Solutions has retained its contract to process Medicare claims and root out fraud on behalf of the CMS. The contract has one base year and six option years and is worth more than $313 million, according to an award notice. The CMS chose Noridian to continue work as the Medicare administrative contractor for Alaska, ... Read More
Planned Parenthood loses bid to stall Title X funding changes A federal judge late Monday tossed a petition by Planned Parenthood affiliates and the American Civil Liberties Union to block HHS’ new funding criteria for the Title X family planning program from taking effect this year. The ruling from U.S. District Judge Trevor McFadden in Washington leaves current grantees in limbo as they wait for HHS’ ... Read More
4 takeaway questions as the Senate looks at healthcare costs The Senate health panel on Tuesday grappled with how new policies could curb the ever-increasing costs of the U.S. health system. The lawmakers came away with several questions that likely will recur as the federal government pushes forward with the shift to value-based care. From standardized “care products” to benchmark pricing, here are four issues lawmakers ... Read More
Pediatric Gene Therapy The European approvals of Glybera® in 2012 and Strimvelis® in 2016 seem likely to be the vanguard of the therapeutic revolution heralded by the decoding of the human genome. Both of these treatments originated from academic centers of excellence and became the subjects of agreements with pharmaceutical companies (Uniqure/Chiesi and GSK, respectively) with the experience ... Read More
The Case for Intelligent Design (and Infrastructure) in Life Science Biologics R&D New White Paper from IDC Health Insights examines industry trends, new challenges and emerging capabilities in biologics. With many recent blockbuster patents expiring, the pharmaceutical industry finds itself in the middle of a transformation. Leading life science organizations are updating their business strategies to include the pursuit of a new market opportunity – the discovery and development ... Read More